Cardiac surgeon Yuriy Dudiy, MD, implanted the device in a 63-year-old male diagnosed with advanced heart failure on July 18.
Impella BTR received FDA investigational device exemption in December 2021. It is a percutaneous forward-flow heart pump capable of greater than 6 liters of blood flow per minute. Less invasive than current left ventricular assist devices, it can be implanted through a small incision in the chest.
The device, developed by medical technology company Abiomed, is designed to provide patients with chronic heart failure a longer-term, minimally invasive heart pump option.
Hackensack medical center is one of five hospitals in the U.S. selected to participate in the FDA-approved clinical trial.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
